Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Original New Drug Application Approvals by US FDA (16 - 30 November 2018)

30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

AEMCOLO
  • Active Ingredient(s): Rifamycin
  • Strength: 192 MG
  • Dosage Form(s) / Route(s): Tablet, Delayed Release; Oral
  • Company: Cosmo Technologies LTD
  • Approval Date: 16 Nov 2018
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated for the treatment of travelers’ diarrhea caused by noninvasive strains of Escherichia coli in adults
  • Approved Label16 Nov 2018 (PDF)
TEMIXYS
  • Active Ingredient(s): Lamivudine; Tenofovir Disoproxil Fumarate
  • Strength: 300 MG; 300 MG
  • Dosage Form(s) / Route(s): Tablet; Oral
  • Company: Medline Industries Inc
  • Approval Date: 16 Nov 2018
  • Submission Classification: Type 5 - New Formulation or New Manufacturer
  • Indication(s): Indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg
  • Approved Label: 16 Nov 2018 (PDF)
READYPREP CHG
  • Active Ingredient(s): Chlorhexidine Gluconate
  • Strength: 2%
  • Dosage Form(s) / Route(s): Cloth; Topical
  • Company: Medline Industries Inc
  • Approval Date: 20 Nov 2018
  • Submission Classification: Type 5 - New Formulation or New Manufacturer
  • Indication(s): Not Available
  • Approved Label: Not Available
GAMIFANT
  • Active Ingredient(s): Emapalumab-LZSG
  • Strength: 10MG/2ML; 50ML/10ML
  • Dosage Form(s) / Route(s): Injectable; Injection
  • Company: Novimmune S.A.
  • Approval Date: 20 Nov 2018
  • Submission Classification: Not Available
  • Indication(s): Indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy
  • Approved Label20 Nov 2018 (PDF)
DAURISMO
  • Active Ingredient(s): Glasdegib
  • Strength: 25MG; 100MG
  • Dosage Form(s) / Route(s): Tablet; Oral
  • Company: Pfizer Inc
  • Approval Date: 21 Nov 2018
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy
  • Approved Label21 Nov 2018 (PDF)
SPY AGENT GREEN
  • Active Ingredient(s): Indocyanine Green
  • Strength: 25MG
  • Dosage Form(s) / Route(s): Power; Intravenous
  • Company: Novadaq Technologies ULC
  • Approval Date: 21 Nov 2018
  • Submission Classification: Type 5 - New Formulation or New Manufacturer
  • Indication(s): Indicated for use with a fluorescence imaging device for: 
  • Approved Label21 Nov 2018 (PDF)
VITRAKVI
  • Active Ingredient(s): Larotrectinib
  • Strength: 25MG; 100MG
  • Dosage Form(s) / Route(s): Capsule; Oral
  • Company: Loxo Oncology Inc
  • Approval Date: 26 Nov 2018
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated for the treatment of adult and pediatric patients with solid tumors that: 
    • have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,  
    • are metastatic or where surgical resection is likely to result in severe morbidity, and 
    • have no satisfactory alternative treatments or that have progressed following treatment. 
  • Approved Label26 Nov 2018 (PDF)
FIRDAPSE
  • Active Ingredient(s): Amifampridine
  • Strength: 10MG
  • Dosage Form(s) / Route(s): Tablet; Oral
  • Company: Catalyst Pharma Inc
  • Approval Date: 28 Nov 2018
  • Submission Classification: Type 1 - New Molecular Entity
  • Indication(s): Indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults .
  • Approved Label28 Nov 2018
XOSPATA
  • Active Ingredient(s): Gilteritinib
  • Strength: 40MG
  • Dosage Form(s) / Route(s): Tablet; Oral
  • Company: Astellas
  • Approval Date: 28 Nov 2018
  • Submission Classification: Type 1 - New Molecular Entity    
  • Indication(s): Indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
  • Approved Label28 Nov 2018
TRUXIMA
  • Active Ingredient(s): Rituximab-abbs
  • Strength: 100MG/10ML (10 MG/ML); 500MG/50ML (10 MG/ML)
  • Dosage Form(s) / Route(s): Injectable; Injection
  • Company: Celltrion Inc
  • Approval Date: 28 Nov 2018 
  • Submission Classification: Not Available
  • Indication(s): Indicated for the treatment of adult patients with Non-Hodgkin’s Lymphoma (NHL) 
  • Approved Label: 28 Nov 2018 (PDF)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.